EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and…
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportBoard of DirectorsOur…
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents…
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider…
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
Calgary, Alberta--(Newsfile Corp. - December 18, 2023) - The Newly Institute ("Newly" or the "Company") is pleased to report the…
Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,…
VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing…
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located…
BRENTWOOD, TN / ACCESSWIRE / December 5, 2023 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and…